open access

Vol 10, No 3 (2014)
Review paper
Published online: 2014-07-30
Get Citation

Surrogate endpoints in assessment of clinical efficacy and safety of oncology drugs — analysis of AHTAPol recommendations

Magdalena Władysiuk, Daria Szmurło, Piotr Wojciechowski
Onkol. Prak. Klin 2014;10(3):138-147.

open access

Vol 10, No 3 (2014)
REVIEW ARTICLES
Published online: 2014-07-30

Abstract

Treatments in oncology are assessed in terms of clinical efficacy and safety at the stage of therapeutic decisions made by oncologists, but also during reimbursement processes (by Health Technology Assessment bodies). Those assessments are based on analysis of clinical benefits measured by progression-related endpoints (progression free survival — PFS, time to progression — TTP) or by survival (overall survival — OS).

Therapeutic decisions in clinical practice are usually based on so called surrogate endpoints (PFS, TTP, response rate, partial response rate), as opposed to „hard” endpoints like survival (OS). This results from a fact that it is much harder to prove survival benefits in clinical trials, because it usually requires long-term follow-up studies and large numer of enrolled patients. This raises a question of whether surrogates are correlated with hard clinical enpoints, and how strong the correlation is. All those endpoints have different clinical meaning, different significance for patients and also different impact on reimbursement decisions.

The aim of this paper was to present definitions of the most commonly used oncology endpoints, show differences and similarities between them and to analyze what is their impact on reimbursement recommendations made by Polish Agency for Health Technology Assessment.

Abstract

Treatments in oncology are assessed in terms of clinical efficacy and safety at the stage of therapeutic decisions made by oncologists, but also during reimbursement processes (by Health Technology Assessment bodies). Those assessments are based on analysis of clinical benefits measured by progression-related endpoints (progression free survival — PFS, time to progression — TTP) or by survival (overall survival — OS).

Therapeutic decisions in clinical practice are usually based on so called surrogate endpoints (PFS, TTP, response rate, partial response rate), as opposed to „hard” endpoints like survival (OS). This results from a fact that it is much harder to prove survival benefits in clinical trials, because it usually requires long-term follow-up studies and large numer of enrolled patients. This raises a question of whether surrogates are correlated with hard clinical enpoints, and how strong the correlation is. All those endpoints have different clinical meaning, different significance for patients and also different impact on reimbursement decisions.

The aim of this paper was to present definitions of the most commonly used oncology endpoints, show differences and similarities between them and to analyze what is their impact on reimbursement recommendations made by Polish Agency for Health Technology Assessment.

Get Citation

Keywords

oncology, primary endpoint, surrogate endpoint, overall survival, progression-free survival, time to progression, OS, PFS, TTP

About this article
Title

Surrogate endpoints in assessment of clinical efficacy and safety of oncology drugs — analysis of AHTAPol recommendations

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 3 (2014)

Article type

Review paper

Pages

138-147

Published online

2014-07-30

Bibliographic record

Onkol. Prak. Klin 2014;10(3):138-147.

Keywords

oncology
primary endpoint
surrogate endpoint
overall survival
progression-free survival
time to progression
OS
PFS
TTP

Authors

Magdalena Władysiuk
Daria Szmurło
Piotr Wojciechowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl